GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abeona Therapeutics Inc (FRA:PCJ) » Definitions » Cyclically Adjusted PB Ratio

Abeona Therapeutics (FRA:PCJ) Cyclically Adjusted PB Ratio : (As of May. 27, 2024)


View and export this data going back to 1980. Start your Free Trial

What is Abeona Therapeutics Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Abeona Therapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Abeona Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abeona Therapeutics Cyclically Adjusted PB Ratio Chart

Abeona Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Abeona Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Abeona Therapeutics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Abeona Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Abeona Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abeona Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Abeona Therapeutics's Cyclically Adjusted PB Ratio falls into.



Abeona Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Abeona Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Abeona Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.297/131.7762*131.7762
=-0.297

Current CPI (Mar. 2024) = 131.7762.

Abeona Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201406 -987.902 100.560 -1,294.577
201409 -1,101.731 100.428 -1,445.635
201412 4.892 99.070 6.507
201503 3.649 99.621 4.827
201506 44.719 100.684 58.529
201509 49.734 100.392 65.282
201512 47.467 99.792 62.680
201603 45.020 100.470 59.048
201606 41.710 101.688 54.051
201609 41.957 101.861 54.279
201612 58.344 101.863 75.478
201703 55.574 102.862 71.196
201706 49.197 103.349 62.729
201709 46.066 104.136 58.293
201712 76.636 104.011 97.093
201803 72.629 105.290 90.900
201806 72.760 106.317 90.184
201809 67.140 106.507 83.069
201812 61.439 105.998 76.381
201903 54.352 107.251 66.781
201906 48.141 108.070 58.701
201909 42.707 108.329 51.950
201912 48.010 108.420 58.352
202003 35.816 108.902 43.339
202006 31.698 108.767 38.403
202009 28.908 109.815 34.689
202012 21.922 109.897 26.286
202103 20.014 111.754 23.600
202106 17.232 114.631 19.809
202109 16.635 115.734 18.941
202112 6.368 117.630 7.134
202203 4.853 121.301 5.272
202206 3.237 125.017 3.412
202209 2.029 125.227 2.135
202212 1.426 125.222 1.501
202303 0.976 127.348 1.010
202306 0.402 128.729 0.412
202309 0.836 129.860 0.848
202312 0.513 129.419 0.522
202403 -0.297 131.776 -0.297

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Abeona Therapeutics  (FRA:PCJ) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Abeona Therapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Abeona Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Abeona Therapeutics (FRA:PCJ) Business Description

Traded in Other Exchanges
Address
1330 Avenue of the Americas, 33rd Floor, New York, NY, USA, 10019
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its lead clinical programs consist of EB-101, autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, adeno-associated virus-based gene therapy for Sanfilippo syndrome type A, and ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B.

Abeona Therapeutics (FRA:PCJ) Headlines

No Headlines